Anadys Climbs On Hepatitis C Study - FOXBusiness.com
Posted using ShareThis
Subscribe to:
Post Comments (Atom)
skip to main |
skip to sidebar
Viral Matters focuses on all aspects of Direct Acting Antivirals (DAA) and Antiretrovirals in development and on the market.
Pages
Search This Blog
About Me
- Chris Barnes
- Redondo Beach, CA, United States
- A 17 year veteran of Medical Affairs and Commercial functions of the biopharma and pharmaceutical industry, with expertise in Hepatitis and HIV. christopherjbarnes10@gmail.com
Posts
Followers
Blog Archive
-
▼
2010
(110)
-
▼
May
(10)
- Roche Diagnostics gets FDA premarket approval for ...
- Intermune initiates major restructuring plan - wil...
- More on ADVANCE results for Telaprevir from Reuters
- Vertex's Telaprevir exceeds Wall Street expectatio...
- IL28B allele in SOC arm of Anadys Pharmaceuticals ...
- Tibotec to study Protease Inhibitor TMC435 Photose...
- Erythropoiesis Stimulating Agents (ESAs) not allow...
- Anadys Climbs On Hepatitis C Study - FOXBusiness.com
- University of Edinburgh scientists develop new tes...
- Vertex Awaits Final Proof that Hepatitis C Drug Works
-
▼
May
(10)
No comments:
Post a Comment